Recent Quotes (30 days)

You have no recent quotes
chg | %

Cynata Therapeutics Ltd  

(Public, ASX:CYP)   Watch this stock  
Find more results for CYP
0.630
-0.015 (-2.33%)
Oct 20 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.62 - 0.65
52 week 0.37 - 0.81
Open 0.64
Vol / Avg. 203,150.00/169,142.00
Mkt cap 56.74M
P/E     -
Div/yield     -
EPS -0.05
Shares 90.06M
Beta     -
Inst. own     -
Nov 17, 2017
Cynata Therapeutics Ltd Annual Shareholders Meeting - 9:30AM GMT+11 - Add to calendar
Nov 16, 2017
Cynata Therapeutics Ltd Annual Shareholders Meeting (Estimated) - 9:30AM GMT+11 - Add to calendar
Sep 12, 2017
Cynata Therapeutics Ltd at Rodman & Renshaw Global Investment Conference
Aug 24, 2017
Preliminary 2017 Cynata Therapeutics Ltd Earnings Release
  

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin -5131.73% -4832.37%
Operating margin -5131.73% -6688.33%
EBITD margin - -6391.21%
Return on average assets -63.60% -39.11%
Return on average equity -65.48% -40.57%
CDP Score - -

Address

Suite 1, 1233 High Street, Armadale
MELBOURNE, VIC 3143
Australia
+61-3-98245254 (Phone)
+61-3-98227735 (Fax)

Website links

Description

Cynata Therapeutics Limited is a stem cell and regenerative medicine company. The Company is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, Cymerus. Its Cymerus technology facilitates manufacture of MSCs from a single donor and a single donation. The Company's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). The Company's technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Cymerus platform provides a source of MSCs that is independent of donor limitations and provides an off-the-shelf stem cell platform for therapeutic product use. The Company's MSCs produced using Cymerus technology, can be used to treat unrelated patients, without any need to match the recipient to the donor.

Officers and directors

Paul Kevin Wotton Ph.D. Chairman of the Board
Age: 56
Ross Alexander Macdonald Ph.D. Chief Executive Officer, Managing Director, Executive Director
Peter Webse Company Secretary, Non-Executive Director
Stewart James Washer Ph.D. Non-Executive Director
Age: 44
John C. Chiplin Ph.D. Non-Executive Independent Director
Age: 57